{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-111484","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.596582+00:00","generated_at":"2026-05-16T20:19:59.034448+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Coherus recasts FY 2024/2023 financials for UDENYCA divestiture as discontinued operations","bullets":["UDENYCA sale to Intas completed April 11, 2025 for $483.4M upfront cash including $118.4M inventory.","Company eligible for two additional $37.5M earn-out payments.","Recast financials for FY 2024 and 2023 show biosimilar businesses (UDENYCA, YUSIMRY, CIMERLI) as discontinued operations.","Recast is for incorporation into a Form S-3 registration statement filed Nov 13, 2025.","No other events after 2024 10-K filing are reflected except discontinued ops presentation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-111484","json":"https://secwatch.observer/filing/0001104659-25-111484.json","markdown":"https://secwatch.observer/filing/0001104659-25-111484.md","text":"https://secwatch.observer/filing/0001104659-25-111484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000110465925111484/0001104659-25-111484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000110465925111484/chrs-20251113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:19:59.034448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}